275 related articles for article (PubMed ID: 10209002)
1. Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase.
Kokkonen JO; Kuoppala A; Saarinen J; Lindstedt KA; Kovanen PT
Circulation; 1999 Apr; 99(15):1984-90. PubMed ID: 10209002
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
[TBL] [Abstract][Full Text] [Related]
3. Identification of kallidin degrading enzymes in the isolated perfused rat heart.
Wolfrum S; Dendorfer A; Dominiak P
Jpn J Pharmacol; 1999 Jan; 79(1):117-20. PubMed ID: 10082326
[TBL] [Abstract][Full Text] [Related]
4. Kinin-degrading pathways in the human heart.
Kokkonen JO; Lindstedt KA; Kuoppala A; Kovanen PT
Trends Cardiovasc Med; 2000 Jan; 10(1):42-5. PubMed ID: 11150728
[TBL] [Abstract][Full Text] [Related]
5. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
[TBL] [Abstract][Full Text] [Related]
6. Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11.
Raut R; Rouleau JL; Blais C; Gosselin H; Molinaro G; Sirois MG; Lepage Y; Crine P; Adam A
Am J Physiol; 1999 May; 276(5):H1769-79. PubMed ID: 10330262
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma.
Kuoppala A; Lindstedt KA; Saarinen J; Kovanen PT; Kokkonen JO
Am J Physiol Heart Circ Physiol; 2000 Apr; 278(4):H1069-74. PubMed ID: 10749699
[TBL] [Abstract][Full Text] [Related]
8. Role of ACE and NEP in bradykinin-induced relaxation and contraction response of isolated porcine basilar artery.
Miyamoto A; Murata S; Nishio A
Naunyn Schmiedebergs Arch Pharmacol; 2002 May; 365(5):365-70. PubMed ID: 12012022
[TBL] [Abstract][Full Text] [Related]
9. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
[TBL] [Abstract][Full Text] [Related]
10. Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study.
Blais C; Drapeau G; Raymond P; Lamontagne D; Gervais N; Venneman I; Adam A
Am J Physiol; 1997 Nov; 273(5):H2263-71. PubMed ID: 9374762
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme inhibition modifies angiotensin but not kinin peptide levels in human atrial tissue.
Campbell DJ; Duncan AM; Kladis A
Hypertension; 1999 Aug; 34(2):171-5. PubMed ID: 10454436
[TBL] [Abstract][Full Text] [Related]
12. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.
Zhang X; Recchia FA; Bernstein R; Xu X; Nasjletti A; Hintze TH
J Pharmacol Exp Ther; 1999 Feb; 288(2):742-51. PubMed ID: 9918584
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme and neutral endopeptidase modulate smokeless tobacco-induced increase in macromolecular efflux from the oral mucosa in vivo.
Gao XP; Suzuki H; Olopade CO; Pakhlevaniants S; Rubinstein I
J Lab Clin Med; 1997 Oct; 130(4):395-400. PubMed ID: 9358078
[TBL] [Abstract][Full Text] [Related]
14. Kininase II-type enzymes. Their putative role in muscle energy metabolism.
Dragović T; Minshall R; Jackman HL; Wang LX; Erdös EG
Diabetes; 1996 Jan; 45 Suppl 1():S34-7. PubMed ID: 8529798
[TBL] [Abstract][Full Text] [Related]
15. Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction.
Blais C; Lapointe N; Rouleau JL; Clément R; Gervais N; Geadah D; Adam A
Peptides; 2001 Jun; 22(6):953-62. PubMed ID: 11390026
[TBL] [Abstract][Full Text] [Related]
16. Neutral endopeptidase and angiotensin-converting enzyme inhibitors increase nitric oxide production in isolated canine coronary microvessels by a kinin-dependent mechanism.
Zhang X; Nasjletti A; Xu X; Hintze TH
J Cardiovasc Pharmacol; 1998 Apr; 31(4):623-9. PubMed ID: 9554814
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed.
Dumoulin MJ; Adam A; Rouleau JL; Lamontagne D
J Cardiovasc Pharmacol; 2001 Apr; 37(4):359-66. PubMed ID: 11300648
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of bradykinin agonists and antagonists by plasma aminopeptidase P.
Ward PE; Chow A; Drapeau G
Biochem Pharmacol; 1991 Jul; 42(4):721-7. PubMed ID: 1651078
[TBL] [Abstract][Full Text] [Related]
19. Neutral endopeptidase and angiotensin converting enzyme inhibitors potentiate kinin-induced contraction of ferret trachea.
Dusser DJ; Nadel JA; Sekizawa K; Graf PD; Borson DB
J Pharmacol Exp Ther; 1988 Feb; 244(2):531-6. PubMed ID: 3279179
[TBL] [Abstract][Full Text] [Related]
20. Bradykinin degrading activity in cultured human endothelial cells.
Graf K; Gräfe M; Auch-Schwelk W; Baumgarten CR; Bossaller C; Fleck E
J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S16-20. PubMed ID: 1282624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
